| 袁海燕 裴文意 杨晓芬 张胡 叶罗辉.美罗华对CD20 阳性NHL患者血清LDH、beta2- 微球蛋白及预后的影响*[J].现代生物医学进展英文版,2016,16(1):131-134. |
| 美罗华对CD20 阳性NHL患者血清LDH、beta2- 微球蛋白及预后的影响* |
| Influence of Rituximab on the SerumLDH, beta2-MG and Prognosis for CD20Positive Non-Hodgkin's Lymphoma |
| |
| DOI： |
| 中文关键词: 美罗华 非霍奇金淋巴瘤 血清乳酸脱氢酶 beta2-微球蛋白 预后 |
| 英文关键词: Rituximab Non-Hodgkin's lymphoma LDH beta2-MG Prognosis |
| 基金项目:上海市宝山区科委基金项目（12-E-8） |
|
| Hits: 881 |
| Download times: 0 |
| 中文摘要: |
| 目的：分析美罗华对CD20 阳性非霍奇金淋巴瘤(NHL)患者血清乳酸脱氢酶（LDH）、beta2- 微球蛋白（beta2-MG）水平及预后的影
响。方法：对2004 年1 月-2011 年6 月在我院收治的86 例NHL患者，分别采用CHOP（对照组，n=48）与RCHOP（治疗组，n=48）2
种不同的方案进行化疗，每21 天为一个周期，共6 个周期。比较两组临床疗效、不良反应、LDH和beta2-MG 水平变化及预后。结果：
治疗组的ORR 和DCR 分别为77.1 %和89.6 %，均显著高于对照组56.3 %和72.9 %（P<0.05）；化疗后，两组血清LDH、beta2-MG 均
较化疗前明显下降，而治疗组化疗后血清LDH、beta2-MG 均显著低于对照组(P<0.05)；治疗组白细胞减少、恶心呕吐的并发症高于
对照组(P<0.05)；化疗后1、2 年生存率两组之间均无显著性差异（P>0.05），而治疗组化疗后3 年生存率明显升高(P<0.05)。结论：美
罗华联合CHOP方案治疗CD20 阳性NHL患者疗效明显，且耐受性好，可有效调节血清LDH、茁2-MG 水平，提高缓解率，改善患
者预后。 |
| 英文摘要: |
| Objective:To investigate the influence of rituximab on the serum LDH, beta2-MG and prognosis for CD20 positive
non-Hodgkin's lymphoma (NHL).Methods:96 patients with NHL admitted in our hospital from January in 2004 to June in 2011 were
treated by CHOP Regimen(control group, n=48) and RCHOP Regimen(treatment group, n=48), every 21 days for a cycle, 6 cycles in total.
The clinical curative effect, adverse effects, change of LDH and beta2-MG, prognosis between the two groups were compared.Results:The ORR and DCR in treatment group (77.1 %, 89.6 %) were significantly higher than those in control group (56.3 %, 72.9 %)(P<0.05).
The level of LDH, beta2-MG reduced in both groups after chemotherapy, and it was more obvious in treatment group than in the control
group with a statistical significance (P<0.05); The toxic effect of leukopenia, nausea and vomiting after chemotherapy in treatment group
was significantly higher than that in control group (P<0.05). There was no significant difference in the 1-year, 2-year survival rate after
chemotherapy between the two groups (P>0.05), while 3-year survival rate in treatment group was significantly higher than that in control
group (P<0.05).Conclusion:Combination use of rituximab with CHOP regimen for CD20 positive NHL patients can achieve obvious
effect and well toleration, and can contribute to adjust level of serumLDH and beta2-MG, improve the prognosis. |
|
View Full Text
View/Add Comment Download reader |
| Close |
